Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface.
作者信息
Sandri Giovanni Battista Levi, Lai Quirino
机构信息
Division of General Surgery and Liver Transplantation, San Camillo Hospital, Rome, Italy. (Email:
Hepato-bilio-pancreatic and Liver Transplant Unit.
出版信息
Transl Gastroenterol Hepatol. 2018 Feb 6;3:9. doi: 10.21037/tgh.2018.01.10. eCollection 2018.
Abstract
摘要
相似文献
1
Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface.
Transl Gastroenterol Hepatol. 2018 Feb 6;3:9. doi: 10.21037/tgh.2018.01.10. eCollection 2018.
2
Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.
Dig Dis Sci. 2019 Apr;64(4):976-984. doi: 10.1007/s10620-019-05550-5.
3
Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review.
Int Surg. 2014 Nov-Dec;99(6):779-86. doi: 10.9738/INTSURG-D-13-00122.1.
4
Liver transplantation for hepatocellular carcinoma: current update on treatment and allocation.
Curr Opin Organ Transplant. 2017 Apr;22(2):128-134. doi: 10.1097/MOT.0000000000000385.
5
Current Technical Issues for Surgery of Primary Liver Cancer.
Liver Cancer. 2016 Nov;6(1):51-58. doi: 10.1159/000449345. Epub 2016 Nov 29.
6
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
J Hepatol. 2018 Apr;68(4):783-797. doi: 10.1016/j.jhep.2017.10.004. Epub 2017 Oct 13.
7
Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.
World J Surg Oncol. 2016 May 23;14(1):151. doi: 10.1186/s12957-016-0903-8.
8
Preface.
Clin Liver Dis. 2009 Nov;13(4):xiii-xiv. doi: 10.1016/j.cld.2009.08.001.
9
Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis.
World J Gastroenterol. 2018 Apr 21;24(15):1658-1665. doi: 10.3748/wjg.v24.i15.1658.
10
[Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S257-62. doi: 10.1016/S0399-8320(09)73163-X.
本文引用的文献
1
Downstaging for hepatocellular cancer: harm or benefit?
Transl Gastroenterol Hepatol. 2017 Dec 12;2:106. doi: 10.21037/tgh.2017.11.18. eCollection 2017.
2
Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review.
Transl Gastroenterol Hepatol. 2017 Nov 27;2:98. doi: 10.21037/tgh.2017.11.11. eCollection 2017.
3
Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.
Transl Gastroenterol Hepatol. 2017 Nov 21;2:95. doi: 10.21037/tgh.2017.10.04. eCollection 2017.
4
Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease?
Transl Gastroenterol Hepatol. 2017 Nov 7;2:87. doi: 10.21037/tgh.2017.10.01. eCollection 2017.
5
Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer.
Transl Gastroenterol Hepatol. 2017 Oct 24;2:83. doi: 10.21037/tgh.2017.10.03. eCollection 2017.
6
Hepatocellualr cancer and liver transplantation: from the tower of babel towards a uniform language.
Transl Gastroenterol Hepatol. 2017 Oct 18;2:82. doi: 10.21037/tgh.2017.09.12. eCollection 2017.
7
Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?
Transl Gastroenterol Hepatol. 2017 Oct 12;2:80. doi: 10.21037/tgh.2017.09.06. eCollection 2017.
8
Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?
Transl Gastroenterol Hepatol. 2017 Sep 27;2:78. doi: 10.21037/tgh.2017.09.01. eCollection 2017.
9
Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.
Transl Gastroenterol Hepatol. 2017 Sep 21;2:75. doi: 10.21037/tgh.2017.09.04. eCollection 2017.
10
Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?
Transl Gastroenterol Hepatol. 2017 Sep 21;2:74. doi: 10.21037/tgh.2017.08.07. eCollection 2017.
Zotero 插件